Scenic Biotech

Some people stay healthy despite carrying disease-causing genes – thanks to ‘genetic modifiers’ that suppress the effects of those mutations.

Scenic Biotech is harnessing this natural resilience to develop modifier therapies: a new approach that rebalances health by targeting genes that can counteract disease. With one of the world’s largest genetic modifier data sets, the company is advancing a pipeline of treatments for rare diseases and cancer, with a first-in-class lead program PLA2G15 inhibitor that modifies lysosomal diseases.